We will identify plasma proteomics biomarkers for early diagnosis of lung cancer.

We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients and controls. Artificial intelligent (AI) assisted proteomics classifier will be developed for early diagnosis of lung cancer.

Inclusion Criteria:

• CT screening results showed that the size of pulmonary nodules was more than 5mm
• No treatment related to pulmonary nodules/lung cancer (including surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy, etc.)
• Complete clinical and imaging data
• Chest CT/ low-dose spiral CT reports can be provided in the last 3 months
• Voluntarily sign informed consent

Exclusion Criteria:

• There is a history of tumor
• Clinically uncontrolled active infections, such as acute pneumonia, tuberculosis, etc.
• Received any treatment related to pulmonary nodules, such as antibiotics and hormones, in the past 4 weeks
• Complicated with other tumors and serious diseases of the heart, liver, kidney, brain, blood and other systems
• Participated in other clinical trials within the last 3 months
• Combined with liver and kidney insufficiency, hypoproteinemia and other diseases affecting protein content
• You are pregnant or breastfeeding

Study group: Patients with suspected or confirmed diagnosis of lung cancer. Control group: Non-cancer subjects including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.